Jul
08
2026
TG Therapeutics Launches Phase 2 Trial of BRIUMVI in Treatment-Resistant Schizophrenia – The Clinical Trial Vanguard
TG Therapeutics Launches Phase 2 Trial of BRIUMVI in Treatment-Resistant Schizophrenia The Clinical Trial Vanguard